EANO Seminars General Information

EANO Seminars 2024: Foundations in Neuro-Oncology

General Information:

The EANO Seminars (previously the EANO Winter School) aims to provide an update on the recent advances in the pathogenesis and management of CNS tumors with particular attention devoted to the application in the clinical practice. The educational event will include lectures and case-based workshops, and is aimed to attract scientists, physicians and healthcare professionals involved in diagnosis and treatment of brain tumors.

The main target group are young EANO Youngsters, especially junior staff from all over Europe.

Date: March 15-16, 2024 (arrival Thursdays evening, Friday full day, Saturday until early afternoon)

Venue:
Nencki Institute of Experimental Biology PAS
Address: 3 Pasteur Street, 02-093 Warszawa,
Website: http://en.nencki.gov.pl/

Participants:

EANO Seminars is intended for physicians from all disciplines managing brain tumour patients including nurses, researchers, technicians and allied health professionals with an interest in neuro-oncology. Participants are ideally EANO members, with a focus on young EANO members, selection is based on motivation statement and training background.

 

Registration Fees:

Registration fee for EANO members: EUR 80,-
Registration fee for non-members: EUR 150,-

You are very welcome to become an EANO member. To register for EANO membership, please click here

The registration will cover course participation, educational material, coffee breaks on Friday and Saturday and lunch and dinner on the Friday evening.

The registration does not cover accommodation or travel. Please book your accommodation directly by yourself.

Please note the EANO Seminars is not EACCME accredited.

 

Application:

Registration is now closed.

 

Programme

(update 15.01.2024)

Chairs: Stephen Price, UK (EANO, Education Committee), Jan-Michael Werner, GE (EANO Youngster Committee) and Bozena Kaminska, PL (Local Organizer)
Organizing Committee: Stephen Price, UK, Jan-Michael Werner, GE, Bozena Kaminska, PL, Aleksandra Ellert-MIklaszewska, PL, Wiesława Grajkowska, PL

Day 1 (Friday)

08:00 – 08:45 Registration
08:45 – 09:00 Welcome and Introduction to course objectives,
B. Kaminska (PL), S. Price (UK)

09.00 – 11.00 Contemporary issues in the management of rare brain tumors: SEGAS, gangliogliomas, germ cell tumors, vestibular schwannomas, Amélie Darlix (FR)
09:00-09:20 The WHO classification 2016, W. Grajkowska, Warsaw (PL)
09:20-09:40 When resection matters? Radosław Rola (PL)
09:40-10:00 Innovative approaches in radiotherapy and combination with chemotherapy, Frederic Dhérmain (FR)
10:00-10:20 Targeted agents as a new option , Riccardo Soffietti (IT)
10:20-10:40 Toward the designing of clinical trials in rare tumors, Enrico Franceschi (IT)
10:40-11:00 Discussion

11:00 – 11:30 Coffee Break

11:30 – 13:00 General case discussion, moderators: Radosława Rola (PL), Michael Weller (CH)
(presented by attendees)

13:00 – 14:00 Lunch Break

14:00 – 16:00 Immunology in Neuro-Oncology: where we are and where are we going? Bozena Kaminska (PL), Christel Herold-Mende (GE)
14:00-14:20 General concepts of immune response in brain tumors, Bozena Kaminska (PL)
14:20-14:40 Challenges in immunotherapy of glioma, Michael Weller (CH)
14:40-15:00 Challenges in immunotherapy of brain metastases, Christel Herold-Mende (GE)

15:00-15:20 Neurological complications of checkpoint inhibitors, Ricardo Soffietti (IT)
15:20-15:40 Systemic complications of checkpoint inhibitors, Evangelia Razis (GR)
15:40-16:00 Discussion

16:00 – 16:30 Coffee Break

16:30 – 18:00 Unmet needs and opportunities to advance therapies for GBM, Frederic Dhérmain (FR), Susan Short (UK)
16:30-16:50 Searching for biomarkers Jakub Godlewski (PL)
16:50-17:10 Preclinical studies: new insights? Serena Pellegata, (IT)
17:10-17:30 Image-guided delivery of novel therapeutic approaches for GBM Gabriela Kramer-Marek (UK, PL)
Discussion

18:30 Networking Dinner (TBC)

Day 2 (Saturday)

09:00 – 11:00 Case-based Workshop: The problem of monitoring in primary CNS tumorsFrederic Dhérmain (FR)
09:00-09:20 What about Meningioma: spontaneous and as part of rarer tumour predisposition syndromes (NF2 and other schwannomatosis), Oliver Hanemann (UK)
09:20-09:40 What about glioblastomas? Evangelia Razis (GR)
09:40-10:00 What about lower grade gliomas? Roberta Rudà (IT)
10:00-10:20 Measuring quality of life and what matters to patients Helen Bulbeck (UK)
10:20-10:40 Long-term survival and sequalae of treatments Amélie Darlix (FR)
10:40-11:00 Discussion

11:00 – 11:30 Coffee break

11:30 – 13:00 Questions to the experts, Gabriela Kramer-Marek (UK, PL)
11:30-11:50 Amino acid PET in primary and secondary brain tumors Norbert Galldiks (DE)
11:50-12:10 Which are the important advances in immunotherapy for brain tumours? Susan Short (UK)
12:10-12:30 How to choose between SRS and fractionated SRS? Frederic Dhérmain, (FR)

12:30 – 13:00: Farewell Lecture: CAR-T cells in cancer therapy, R. Zagozdzon, Warsaw/PL

13:00 – 13:15 Final remarks and adjourn